Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 11, 2015, Pages 2047-2060

  Hochhaus, Andreas ^a   Baccarani, Michele ^b   Giles, Francis J ^c   le Coutre, Philipp D ^d   Müller, Martin C ^e   Reiter, Andreas ^e   Santanastasio, Helene ^f   Leung, Mimi ^f   Novick, Steven ^f   Kantarjian, Hagop M ^g  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Northwestern University Feinberg School of Medicine   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

Aggressive systemic mastocytosis; Indolent systemic mastocytosis; KIT D816V; Nilotinib; Systemic mastocytosis; Tyrosine kinase inhibitor

Indexed keywords

NILOTINIB; TRYPTASE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BONE PAIN; CANCER MORTALITY; CELL INFILTRATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE MUTATION; HEADACHE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MAST CELL; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SYSTEMIC MASTOCYTOSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; IMMUNOLOGY; LEUKOCYTE COUNT; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MORTALITY; MYELOPROLIFERATIVE DISORDERS; NEUTROPHIL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NEUTROPHILS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84951567087     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1988-0     Document Type: Article

References (63)

1. Akin C, Metcalfe DD (2004) The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 114:13–19
2. Andersen CL, Kristensen TK, Severinsen MT et al (2012) Systemic mastocytosis—a systematic review. Dan Med J 59:A4397
3. Buet D, Gallais I, Lauret E et al (2012) Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to kit inhibitors in leukemia. Blood 119:4228–4241
4. Casassus P, Caillat-Vigneron N, Martin A et al (2002) Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 119:1090–1097
5. Erben P, Schwaab J, Metzgeroth G et al (2014) The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 93:81–88
6. Fabbro D, Ruetz S, Bodis S et al (2000) PKC412—a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15:17–28
7. Fuller SJ (2012) New insights into the pathogenesis, diagnosis, and management of mastocytosis. Hematol Oncol Clin North Am 26:1143–1168
8. Furitsu T, Tsujimura T, Tono T et al (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92:1736–1744
9. Gajiwala KS, Wu JC, Christensen J et al (2009) KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 106:1542–1547
10. Garcia-Montero AC, Jara-Acevedo M, Teodosio C et al (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108:2366–2372
11. Giles FJ, Kantarjian HM, le Coutre PD et al (2012) Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26:959–962
12. Giles FJ, le Coutre PD, Pinilla-Ibarz J et al (2013) Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27:107–112
13. ® (imatinib) [prescribing information] (2015) Novartis Pharmaceuticals Corporation, East Hanover
14. Gleixner KV, Mayerhofer M, Aichberger KJ et al (2006) PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107:752–759
15. Gleixner KV, Mayerhofer M, Cerny-Reiterer S et al (2011) KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 118:1885–1898
16. Gotlib J, DeAngelo DJ, George TI et al (2010) KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial [abstract 316]. Blood 116
17. Gotlib J, Pardanani A, Akin C et al (2013) International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 121:2393–2401
18. Gotlib J, Kluin-Nelemans HC, George T et al (2014) Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from the fully accrued global phase 2 CPKC412D2201 trial [abstract 636]. Blood 124
19. Harir N, Boudot C, Friedbichler K et al (2008) Oncogenic kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood 112:2463–2473
20. Hermine O, Hirsh I, Damaj G et al (2010) Long term efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 44 patients [abstract 1982]. Blood 116
21. Hochhaus A, Ottmann OG, Lauber S et al (2006) A phase II study of nilotinib, a novel inhibitor of c-kit, PDGFR, and bcr-abl, administered to patients with systemic mastocytosis [abstract 2703]. Blood 108
22. Horny HP, Akin C, Metcalfe DD, Escribano L, Bennett JM, Valent P (2008) Mastocytosis (mast cell disease). In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours. International Agency for Research and Cancer (IARC) Press, Lyon, pp 54–63
23. Kantarjian H, Giles F, Wunderle L et al (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542–2551
24. Kantarjian HM, Giles F, Gattermann N et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540–3546
25. Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260–2270
26. Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, Moller MB, Hospital Mastocytosis Centre Odense University (2013) Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis. Eur J Haematol 91:106–111
27. Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cardo C (1994) Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 42:1417–1425
28. le Coutre PD, Giles FJ, Hochhaus A et al (2012) Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 26:1189–1194
29. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A (2009a) Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 84:790–794
30. Lim KH, Tefferi A, Lasho TL et al (2009b) Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 113:5727–5736
31. Lombardo LJ, Lee FY, Chen P et al (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual src/abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658–6661
32. Manley PW, Drueckes P, Fendrich G et al (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804:445–453
33. Matito A, Morgado JM, Alvarez-Twose I et al (2013) Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. PLoS One 8:e76116
34. National Cancer Institute (2006) Common terminology criteria for adverse events (CTCAE), version 3.0
35. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L, REMA (2007) Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 138:12–30
36. Pardanani A (2012) Systemic mastocytosis: disease overview, pathogenesis, and treatment. Hematol Oncol Clin North Am 26:1117–1128
37. Pardanani A (2015) Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. Am J Hematol 90:250–262
38. Pardanani A, Tefferi A (2010a) A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol 84:371–378
39. Pardanani A, Tefferi A (2010b) Proposal for a revised classification of systemic mastocytosis. Blood 115:2720–2721
40. Pardanani A, Reeder TL, Kimlinger TK et al (2003) Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res 27:739–742
41. Paul C, Sans B, Suarez F et al (2010) Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 85:921–925
42. Pittoni P, Piconese S, Tripodo C, Colombo MP (2011) Tumor-intrinsic and -extrinsic roles of c-kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene 30:757–769
43. Quintas-Cardama A, Jain N, Verstovsek S (2011) Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis. Cancer 117:5439–5449
44. Schwaab J, Schnittger S, Sotlar K et al (2013) Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 122:2460–2466
45. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C (2006) Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108:286–291
46. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10
47. Tasigna (nilotinib) [prescribing information] (2015) Novartis Pharmaceuticals Corporation, East Hanover
48. Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14–22
49. US National Institutes of Health (2015) ClinicalTrials.gov. Accessed 9 Mar 2015
50. Ustun C, Corless CL, Savage N et al (2009) Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res 33(5):735–741
51. Valent P, Horny HP, Escribano L et al (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25:603–625
52. Valent P, Akin C, Sperr WR et al (2003) Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122:695–717
53. Valent P, Akin C, Escribano L et al (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37:435–453
54. Valent P, Sperr WR, Akin C (2010) How I treat patients with advanced systemic mastocytosis. Blood 116:5812–5817
55. Valent P, Akin C, Arock M et al (2012) Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 157:215–225
56. Vega-Ruiz A, Cortes JE, Sever M et al (2009) Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 33:1481–1484
57. Verstovsek S (2013) Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol 90:89–98
58. Verstovsek S, Akin C, Manshouri T et al (2006) Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 30:1365–1370
59. Verstovsek S, Tefferi A, Cortes J et al (2008) Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14:3906–3915
60. von Bubnoff N, Gorantla SH, Kancha RK, Lordick F, Peschel C, Duyster J (2005) The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 19:1670–1671
61. Weisberg E, Boulton C, Kelly LM et al (2002) Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1:433–443
62. Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129–141
63. Woodward T (2003) Systemic mastocytosis. Curr Treat Options Gastroenterol 6:35–38